COST OF COMORBIDITIES IN PEOPLE LIVING WITH HIV IN DENMARK by Axelsen, Flemming et al.
ISPOR Europe 2018 Abstract.							June 12th 2018
COST OF COMORBIDITIES IN PEOPLE LIVING WITH HIV IN DENMARK
A retrospective register study in Denmark 

Max.: 300 words 		Currently: 295
Authors:
Axelsen F., Market Access Manager, Gilead Sciences Denmark
Ording AG., Postdoc, Ph.D., Aarhus University 
Ehlers LH., Professor Health Economics, Aalborg University

This study is funded by Gilead Sciences, Denmark

OBJECTIVES:
Since the introduction of highly active antiretroviral therapy in 1996-1997 both mortality and morbidity among persons infected with HIV has decreased dramatically. Still, HIV-infected persons’ mortality remains higher than in uninfected persons and at time of diagnosis almost 10% has at least one comorbid disease diagnosed.  This study assesses the HIV infected population to a matched non-HIV infected cohort in Denmark with respect to the types of non-communicable disease, the related healthcare resource utilization, direct and indirect health care costs.

METHODS:
Data is collected from Danish registries where unique identification numbers (CPR) assigned to every Danish citizen allows for electronic record linkage among multiple databases. The different registries used make it possible to analyze health care utilization, use of social benefits, income, employment and education i.e. 
Results will be presented per patient per year (PPPY), aggregated and total costs per non-communicable disease stratified by age, sex, time on antiretroviral therapy and calendar time.

RESULTS: 
The study includes more than 500 HIV positive patients and a match-control population of 5.000 randomly selected HIV negative citizens.
According to each comorbid condition present at time of HIV diagnosis we will; estimate the use of health care for In-patient and number of outpatient visits at hospitals and use of health services provided by the general practitioners including prescribed medicine and any GP referral within 1, 2, 5, and 10 years after HIV diagnosis or index date (control cohort).
The study evaluates the associated cost of managing those comorbidities from a health care perspective as well from a society perspective.

CONCLUSION: 
This study will assess if HIV patients have more comorbidities compared to a HIV negative control group, the study evaluate the associated cost of managing those comorbidities from a health care perspective as well from a societal perspective.

